Comprehensive medication guide to Konvomep including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Commercially insured patients may pay as little as $5 using Azurity's paperless co-pay savings program. Without the program, copays can range from $30–$150 depending on formulary tier. Many plans place Konvomep on Tier 3 or higher and may require prior authorization.
Estimated Cash Pricing
$194–$272 retail for a 90–150 mL bottle (approximately a 30-day supply at standard 40 mg/day dosing); no generic is available as of 2026. With a GoodRx coupon, prices can drop to approximately $197 for a 90 mL bottle at participating pharmacies.
Medfinder Findability Score
45/100
On this page
Konvomep is the brand name for omeprazole and sodium bicarbonate for oral suspension, manufactured by Azurity Pharmaceuticals. It was FDA-approved on August 30, 2022, and became commercially available in early 2023. Konvomep is a prescription liquid medication that combines omeprazole — a proton pump inhibitor (PPI) — with sodium bicarbonate to create a strawberry-flavored oral suspension.
Konvomep is dispensed as a two-bottle kit: one containing omeprazole powder and one containing a sodium bicarbonate diluent. A pharmacist reconstitutes the kit before dispensing. After reconstitution, each mL contains 2 mg omeprazole and 84 mg sodium bicarbonate. Available in 90 mL, 150 mL, and 300 mL bottle sizes.
Konvomep is specifically designed for adult patients who cannot swallow standard capsules or tablets, such as those with dysphagia, or patients requiring medications through a nasogastric or orogastric tube. It is FDA-approved for adults only.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Konvomep works through a two-component mechanism. When taken on an empty stomach, the sodium bicarbonate component rapidly neutralizes stomach acid, temporarily raising gastric pH. This protects the omeprazole from being degraded by acid before it can be absorbed.
Once absorbed into the bloodstream, omeprazole travels to the acid-producing parietal cells in the stomach lining. There, it is converted to its active form and irreversibly binds to the H+/K+ ATPase enzyme — the "proton pump" — blocking the final step in gastric acid production. This binding is irreversible and lasts until new proton pumps are synthesized, giving sustained acid suppression for approximately 24 hours per dose.
Omeprazole is primarily metabolized by the CYP2C19 and CYP3A4 enzymes in the liver. Full therapeutic effect builds over 3–5 days of consistent once-daily dosing, as more and more proton pumps are progressively blocked with each dose. Taking Konvomep at least 1 hour before eating is essential for maximum effectiveness.
40 mg / 20 mL — oral suspension
Standard adult dose for active benign gastric ulcer — 40 mg (20 mL) once daily for 4-8 weeks
40 mg loading + 40 mg maintenance — oral suspension
GI bleeding prevention in critically ill: 40 mg loading dose, then 40 mg at 6-8 hours, then 40 mg daily for 14 days
2 mg/mL — oral suspension (reconstituted)
Concentration after reconstitution — available in 90 mL, 150 mL, and 300 mL kits
Konvomep is not in an official FDA shortage as of 2026, but it is genuinely difficult to find at many retail pharmacies. We rate its findability at 45 out of 100 — reflecting frequent localized availability gaps. Most retail chain pharmacies do not stock Konvomep routinely due to its refrigeration requirements, short shelf life after reconstitution, and relatively low demand compared to standard PPI capsules.
Patients most likely to find Konvomep in stock include those who check hospital outpatient pharmacies, specialty pharmacies, or call ahead to request a special order. Most pharmacies with wholesale accounts can order Konvomep within 24–48 business hours even if they don't carry it routinely.
Rather than spending time calling pharmacies yourself, medfinder calls pharmacies near you to find which ones have Konvomep in stock and texts you the results.
Konvomep is not a controlled substance, meaning any licensed healthcare prescriber can write a prescription for it without special DEA authorization. Prescribers across multiple specialties commonly prescribe Konvomep, including:
Gastroenterologists — most familiar with Konvomep for gastric ulcers and complex GI patients
Intensivists and critical care physicians — for GI bleeding prophylaxis in ICU patients
Internal medicine physicians — for patients with ulcers, GERD, or dysphagia
Primary care physicians (PCPs) — for outpatient management of acid-related conditions in patients unable to swallow capsules
Nurse practitioners (NPs) and Physician assistants (PAs) — licensed to prescribe Konvomep in most states across primary care and specialty settings
Hospitalists — may initiate Konvomep during hospital stays and provide discharge prescriptions
Because Konvomep is not a controlled substance, it can be prescribed via telehealth in most states without restriction. Telehealth platforms specializing in gastroenterology, internal medicine, or general primary care can prescribe Konvomep for appropriate outpatient indications such as GERD and gastric ulcers. Note that the critically ill patient indication requires in-hospital management.
No. Konvomep is not a controlled substance and is not scheduled by the DEA. It does not require any special DEA authorization to prescribe or dispense. Any licensed healthcare provider — including physicians, nurse practitioners, and physician assistants — can prescribe Konvomep without restriction on refills related to scheduling.
Because Konvomep is not controlled, it can generally be prescribed via telehealth without additional restrictions in most states. Your prescriber may still limit refills based on your clinical indication — for example, gastric ulcer treatment is typically 4–8 weeks — so discuss the expected duration of therapy at each appointment.
The most commonly reported side effects of Konvomep include:
Headache
Abdominal pain
Nausea
Diarrhea
Vomiting
Flatulence
Acute tubulointerstitial nephritis (kidney inflammation)
C. difficile-associated diarrhea
Hypomagnesemia (low magnesium) with prolonged use
Bone fractures with long-term high-dose use
Severe cutaneous reactions including Stevens-Johnson syndrome
Cutaneous and systemic lupus erythematosus
Vitamin B-12 deficiency with long-term use
Sodium retention and systemic alkalosis (from sodium bicarbonate component)
Know what you need? Skip the search.
Zegerid (omeprazole/sodium bicarbonate)
Older brand with same active ingredients; available as capsules and powder packets — wider availability than Konvomep
Prilosec (omeprazole)
Delayed-release omeprazole capsules; available OTC and as generic; widely stocked everywhere; not equivalent for tube feeding
Nexium (esomeprazole)
PPI available as capsules and sprinkle granules; sprinkle form compatible with NG tube; widely covered by insurance
Prevacid (lansoprazole)
PPI available as orally disintegrating tablets (ODT) useful for mild dysphagia; also as suspension packets for tube feeding
Protonix (pantoprazole)
PPI available as tablets and IV formulation; widely available as generic; tablet not recommended for crushing in tube-fed patients
Prefer Konvomep? We can find it.
Rilpivirine (Edurant, Complera, Odefsey)
majorContraindicated — PPIs significantly reduce rilpivirine absorption, risking HIV treatment failure and resistance
Nelfinavir (Viracept)
majorContraindicated — omeprazole significantly reduces nelfinavir levels through CYP2C19 inhibition and reduced gastric absorption
Clopidogrel (Plavix)
majorAvoid — omeprazole inhibits CYP2C19 conversion of clopidogrel to active form, reducing antiplatelet efficacy; risk of cardiovascular events in at-risk patients
St. John's Wort
majorAvoid — potent CYP3A4 inducer that significantly reduces omeprazole plasma levels and effectiveness
Rifampin (Rifadin)
majorAvoid — CYP3A4 inducer that dramatically reduces omeprazole levels
Methotrexate
moderateCaution — PPIs may increase methotrexate levels, raising risk of toxicity; monitor closely especially with high-dose methotrexate
Warfarin (Coumadin)
moderateMonitor INR — omeprazole inhibits CYP2C19 metabolism of warfarin; may increase bleeding risk
Tacrolimus (Prograf)
moderateMonitor levels — omeprazole may increase tacrolimus serum concentrations; relevant for transplant patients
Voriconazole (Vfend)
minorMinor — voriconazole increases omeprazole exposure; dosage adjustment not usually required
Konvomep fills an important clinical niche as the only FDA-approved oral liquid suspension kit formulation of omeprazole and sodium bicarbonate. It serves patients who cannot take standard PPI capsules — particularly those with dysphagia, tube feeding requirements, or post-ICU care needs. For these patients, finding Konvomep is not optional — it's a clinical necessity.
The main challenges with Konvomep are availability and cost. Most retail pharmacies don't stock it routinely, and without the Azurity co-pay program, cash prices can reach $200+ per bottle. Patients and providers need to be proactive: start with hospital outpatient and specialty pharmacies, apply savings programs early, and have a clinical alternative plan ready if needed.
If you're struggling to find Konvomep at a pharmacy near you, medfinder can call pharmacies in your area to find which ones have it in stock — saving you time and frustration so you can focus on your health.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Konvomep. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini